NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer’s Disease

NeuroSense Therapeutics Ltd. announced today a collaboration in Alzheimer’s Disease (AD) drug development with Genetika+ , a leader in precision medicine for psychiatry and neurology.